- Home
- GENK vs FBIO Comparison
GENK vs FBIO Comparison
Compare GENK & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- FBIO
- Stock Information
- Founded
- GENK 2011
- FBIO 2006
- Country
- GENK United States
- FBIO United States
- Employees
- GENK N/A
- FBIO N/A
- Industry
- GENK Restaurants
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- FBIO Health Care
- Exchange
- GENK Nasdaq
- FBIO Nasdaq
- Market Cap
- GENK 41.1M
- FBIO 39.4M
- IPO Year
- GENK 2023
- FBIO N/A
- Fundamental
- Price
- GENK $7.53
- FBIO $1.72
- Analyst Decision
- GENK Strong Buy
- FBIO Strong Buy
- Analyst Count
- GENK 3
- FBIO 3
- Target Price
- GENK $13.17
- FBIO $18.00
- AVG Volume (30 Days)
- GENK 60.0K
- FBIO 718.4K
- Earning Date
- GENK 11-12-2024
- FBIO 11-14-2024
- Dividend Yield
- GENK N/A
- FBIO N/A
- EPS Growth
- GENK 483.78
- FBIO N/A
- EPS
- GENK 0.17
- FBIO N/A
- Revenue
- GENK $198,834,000.00
- FBIO $81,501,000.00
- Revenue This Year
- GENK $14.66
- FBIO N/A
- Revenue Next Year
- GENK $21.47
- FBIO $134.70
- P/E Ratio
- GENK $43.70
- FBIO N/A
- Revenue Growth
- GENK 12.50
- FBIO 31.51
- 52 Week Low
- GENK $5.61
- FBIO $1.36
- 52 Week High
- GENK $14.46
- FBIO $4.43
- Technical
- Relative Strength Index (RSI)
- GENK 39.46
- FBIO 41.52
- Support Level
- GENK $7.10
- FBIO $1.72
- Resistance Level
- GENK $8.45
- FBIO $2.27
- Average True Range (ATR)
- GENK 0.51
- FBIO 0.15
- MACD
- GENK -0.08
- FBIO -0.05
- Stochastic Oscillator
- GENK 22.22
- FBIO 0.00
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.